Comparison · NCT00566501-sae
Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205) vs Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205) vs Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205): serious adverse events. Trial comparisons, record NCT00566501-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00566501-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.14 | 0.114 | 0.171 | wilson | |
| Risk in group 2 | 0.169 | 0.132 | 0.213 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0283 | -0.0795 | 0.0195 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.832 | 0.608 | 1.14 | log | |
| Odds ratio, group 1 over group 2 | 0.805 | 0.555 | 1.17 | log | |
Number needed to treat, for one fewer participant with a serious adverse event on Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205) than on Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205) | 35.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205) | Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326 (NCT00478205). | 80 | 570 | EG000 |
| Group 2 | Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205) | Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 10 mg IR in the preceding double-blind study E2020-G000-326 (NCT00478205). | 56 | 332 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From the first dose of study drug up to 2 years 3 months
Source ClinicalTrials.gov
Trial
- Title
- Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease
- NCT number
- NCT00566501
- Phases
- PHASE3
- Conditions
- Alzheimer's Disease
- Interventions
- Donepezil
- Lead sponsor
- Eisai Inc.
- Results first posted
- 2012-06-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00566501?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00566501-sae